References in periodicals archive ?
Since then low dose MTX treatment (10mg once a week) has been successfully initiated, 6 months after discharge she maintained low neutrophil counts (2000-4000/[mm.sup.3]), with no signs of infection and no need for G-CSF administration.
There is a clear need for a better first-line stem cell mobilization agent for both patients and donors that does not involve the use of G-CSF.
According to our findings, the use of maternal G-CSF without fetal catheterization followed by high-dose IA endotoxin is effective to induce fetal funisitis as well as fetal brain and lung injury.
(23,) (24) In the G-CSF group, after the induction of the chemotherapy model, 70 [micro]g/kg of the G-CSF was injected intraperitoneally for 5 consecutive days.
One rat in the control group and one in the BMSCs+ G-CSF group died during the experiment.
IL-8 (D0) correlated with SOFA (D0) (rho = 0.27; p = 0.007), SOFA (D1) (rho = 0.36; p < 0.001), and SOFA (D3) (rho = 0.34; p = 0.001); IL-10 correlated with SOFA (D0) (rho = 0.3; p = 0.01), SOFA (D1) (rho = 0.4; p = 0.001), and SOFA D3 (rho = 0.26; p = 0.045); G-CSF (D0) correlated with SOFA (D1) (rho = 0.25; p = 0.01) and SOFA (D3) (rho = 0.24; p = 0.02); IL-17 (D0) correlated with SOFA (D0) (rho = 0.23; p = 0.01), but there was no correlation with SOFA (D1) or SOFA (D3).
The risk of leukemia transformation is related to the myeloid arrest level in bone marrow, the type of ELANE mutation (C214R, C151Y), the presence of pancytopenia and G-CSF administration.
Results: The mean duration of G-CSF treatment was 1.82+-0.81 days (1.0 - 4.0).
Pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF) receptor agonist, is used to stimulate bone marrow to produce more neutrophils in order to decrease the incidence of infection in patients undergoing chemotherapy.
Then the rabbits were assigned randomly to two groups: six rabbits received G-CSF 100 ug/kg/day subcutaneously for 7 days and six rabbits were considered as control group.
Granulocyte colony-stimulating factor (G-CSF) was the first cytokine identified and introduced into medical practice in order to treat neutropenia and to induce mobilization of hematopoietic stem cells (HSC) in donors before transplantation.